J&J suing Samsung Bioepis over Stelara biosimilar
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Samsung Bioepis, Alvotech/Teva, and Celltrion, says the complaint. The lawsuit has emerged after the first Stelara biosimilar – Amgen’s Wezlana – was approved on 31st October as an ...
Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.
Celltrion’s Stelara biosimilar ustekinumab-stba (Steqeyma ... 4 The ruling against Janssen’s application was considered a success for Samsung Bioepis. As a result, Celltrion was permitted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback